加拿大Axcan Pharma Inc. 
Axcan Pharma Inc. (圣海拉尔山， Mont Saint Hilaire) 宣布在北美的ITAX (itopride)第三期临床测试病人登录，其乱度规划己超越预计之500人目标设计。额外的登记人数尚在筛检过程，公司预定会持续进行临床测试的乱度规划设计至2005年12月底，以符合原订进度。事实上如公司在2005年11月10日所宣布的，参与国际临床测试所需的病人数目，已完成纳入乱度规划进度。这项临床药物发展计划包括两个第三期临床测试，一个是在北美，另一个就是国际临床测试。这项计划的目的在于测试Itopride药物在治疗一种胃肠性疾病，也就是功能性消化不良(Functional Dyspepsia)时的安全性及有效性。Axcan公司希望能够在2006年的前半年可以宣告这项北美第三期临床测试大体结果。临床测试成果细节则较可能会在一个国际胃肠性疾病学术研讨会中发表。
Axcan Pharma is a privately-held, leading specialty pharmaceutical company that develops and markets a wide range of products to treat gastrointestinal diseases and disorders, such as inflammatory bowel disease, cholestatic liver diseases, irritable bowel syndrome, and complications related to pancreatic insufficiency. All Axcan’s activities underscore the Company's single, well-defined Mission - to improve the quality of care and health of patients suffering from gastrointestinal diseases and disorders by providing effective therapies for patients and their specialized caregivers.

Through internal product development and synergistic acquisitions of products and companies, Axcan has built a leadership position in the North American gastroenterology market; just under 85 percent of the Company's business is generated from North American sales. Since Axcan markets its specialized products to a relatively cohesive community of physicians, its sales forces are able to reach this market more easily than pharmaceutical companies with a product portfolio targeting a more diverse range of diseases. Axcan's products are marketed by its own dedicated and specialized sales forces both in North America and the European Union.

Axcan Pharma and its global operations are working hand-in-hand to become a multinational leader for disorders linked to gastroenterology. Currently, the Company markets more than 40 products and dosage strengths worldwide in the field of gastroenterology, including several that hold a leading market position.

In addition to its marketing activities, Axcan carries out research and development of products at an advanced stage of development that it acquires or licenses from third parties. By combining its marketing expertise with its research and development experience, Axcan distinguishes itself from specialty pharmaceutical companies that focus solely on the distribution of products and offers potential licensors the prospect of rapidly expanding the market for their products.

Axcan’s unique expertise in its field, combined with its excellent industry reputation and international reach, has enabled the Company to maintain its consistent growth trend and attain its strong market position. Axcan’s solid and stable base business provides a platform for the Company to capitalize on its proven business strategy, in order to continue to achieve significant future growth.

The Company plans to continue to grow its business by:

increasing market penetration and sales of existing products;
developing and obtaining marketing approval for new products;
in-licensing products and acquiring new products or companies;
development of its research and development portfolio, and
expanding geographically.
Axcan’s corporate headquarters are based outside of Montreal, Quebec, Canada. The Company employs almost 500 people worldwide and has additional offices in both the United States and France.